Global Patent Index - EP 0985415 A1

EP 0985415 A1 2000-03-15 - Uracil reductase inactivators

Title (en)

Uracil reductase inactivators

Title (de)

Uracilreduktasehemmer

Title (fr)

Inhibiteurs de la uracile-reductase

Publication

EP 0985415 A1 (EN)

Application

EP 99202472 A

Priority

  • EP 91917260 A
  • GB 9020930 A

Abstract (en)

Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-fluorouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from halo-substituted C1-4 alkyl, C2-6 alkynyl, or halo substituted C2-6 alkynyl.

IPC 1-7 (main, further and additional classification)

A61K 31/505

IPC 8 full level (invention and additional information)

A61K 31/7105 (2006.01); A61K 31/505 (2006.01); A61K 31/513 (2006.01); A61K 31/70 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 239/54 (2006.01); C07H 19/06 (2006.01)

IPC 8 main group level (invention and additional information)

A61K (2006.01)

CPC (invention and additional information)

A61K 31/70 (2013.01); A61K 9/0031 (2013.01); A61K 9/1623 (2013.01); A61K 9/1635 (2013.01); A61K 9/1652 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/48 (2013.01); A61K 31/505 (2013.01); A61K 31/513 (2013.01); A61K 31/7072 (2013.01); A61K 45/06 (2013.01); C07D 239/54 (2013.01); C07H 19/06 (2013.01)

Combination set (CPC)

  1. A61K 31/505 + A61K 31/505
  2. A61K 45/06 + A61K 31/70 + A61K 31/70
  3. A61K 45/06 + A61K 31/70 + A61K 31/505
  4. A61K 31/7072 + A61K 31/7072 + A61K 31/505
  5. A61K 31/505 + A61K 31/505
  6. A61K 31/505 + A61K 2300/00
  7. A61K 31/7072 + A61K 2300/00

Citation (search report)

  • [XY] DD 122381 A1 19761005
  • [XY] EP 0360018 A1 19900328 - YOSHITOMI PHARMACEUTICAL [JP], et al
  • [XY] US 3324126 A 19670606 - MERTES MATHIAS P, et al
  • [X] STN INTERNATIONAL, KARLSRUHE. FILE CHEMICAL ABSTRACTS. AN=94:145342, XP002123925 & JP S55111420 A 19800828 - ONO PHARMACEUTICAL CO
  • [XY] DATABASE WPI Section Ch Week 198527, Derwent Publications Ltd., London, GB; Class B03, AN 1985-163291, XP002123931
  • [XY] M. BOBEK: "The chemistry and biology of some new nucleoside analogs active against tumor cells", STN INTERNATIONAL, KARLSRUHE. FILE CHEMICAL ABSTRACTS, AN=91:186418, XP002123926 & CHEM. BIOL. NUCLEOSID. NUCLEOTID., 1978, PP. 135-148CHEM. BIOL. NUCLEOSID. NUCLEOTID., 1978, PP. 135-148
  • [XY] R.T. WALKER: "The synthesis and biological properties of some 5-substituted-2'-deoxyuridines", NUCL. ACID RES., SYMP. SER., no. 16, 1985, pages 291 - 294, XP002123927
  • [XY] W.A. SKINNER: "Potential anticancer agents. XXVIII. Synthesis of 5-(chloromethyl)uracil", J. ORG. CHEM., vol. 25, 1960, pages 149 - 151, XP002123928
  • [Y] C. DESGRANGES: "Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice", CANCER RES., vol. 46, no. 3, 1986, pages 1094 - 1101, XP000856003
  • [T] TH. SPECTOR: "5-Ethynyluracil (776C85): an inactivator of uracil reductase that potentiates the antitumour activity of 5-fluorouracil", CURR. OPIN. THER. PAT., vol. 3, no. 12, 1993, pages 1751 - 1754, XP002123930

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IT LI LU NL SE

EPO simple patent family

WO 9204901 A1 19920402; AT 190489 T 20000415; AU 654505 B2 19941110; AU 8540591 A 19920415; BR 1100356 A 20030225; CA 2092435 A1 19920327; CA 2092435 C 20021112; CA 2390654 A1 19920402; CZ 288515 B6 20010711; CZ 288520 B6 20010711; CZ 9300506 A3 19940216; CZ 9501709 A3 19951213; CZ 9600161 A3 19960515; CZ 9600162 A3 19960515; DE 69132052 D1 20000420; DE 69132052 T2 20000803; DK 0550580 T3 20001204; EP 0550580 A1 19930714; EP 0550580 B1 20000315; EP 0985415 A1 20000315; ES 2143465 T3 20000516; FI 112601 B 20031231; FI 931337 A0 19930325; FI 931337 A 19930325; GB 9020930 D0 19901107; GR 3033388 T3 20000929; HK 1004188 A1 20000728; HU 219589 B 20010528; HU 9300863 D0 19930628; HU T63765 A 19931028; IE 20010101 A1 20020320; IL 121947 D0 19980310; IL 99562 A 19991130; IL 99562 D0 19920818; JP 2682739 B2 19971126; JP 3003993 B2 20000131; JP H06504263 A 19940519; JP H1045623 A 19980217; KR 100222329 B1 19991001; MC 2307 A 19930927; MY 128980 A 20070330; NO 313175 B1 20020826; NO 931118 A 19930325; NO 931118 D0 19930325; NO 980717 A 19930325; NO 980717 D0 19980220; NZ 239927 A 19951127; NZ 250799 A 19951127; PT 99041 A 19920831; PT 99041 B 19990226; RU 2194511 C2 20021220; SG 47912 A1 19980417; SK 23393 A3 19930707; SK 281894 B6 20010911; TW 271397 B 19960301; US 2002042392 A1 20020411; US 2007078106 A1 20070405; US 5817664 A 19981006; US 6268374 B1 20010731; US 6297223 B1 20011002; US 7119096 B2 20061010; US 7704971 B2 20100427; ZA 9107667 B 19930325

INPADOC legal status


2003-05-14 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20021112

2001-01-24 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20001206

2000-11-29 [AKX] PAYMENT OF DESIGNATION FEES

- Free text: AT BE CH DE DK ES FR GB GR IT LI LU NL SE

2000-03-15 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 19990728

2000-03-15 [AC] DIVISIONAL APPLICATION (ART. 76) OF:

- Document: EP 550580

2000-03-15 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE